World News – CA – Immutep’s (ASX: IMM) breast cancer therapy for Phase 2 trial in China – The Market Herald


. .

Immutep’s Chinese partner, EOC Pharma, will start a phase 2 clinical trial in patients with metastatic breast cancer.

Encouraging results from Immutep’s ongoing AIPAC Phase IIb study with the lead drug candidate eftilagimod alpha (efti) have confirmed the drug’s potential in combination with the chemotherapy drug paclitaxel.

While the final data will not be available until the middle of next year, a statistically significant increase in overall survival rates has been noted.

These positive results were a motivating factor in EOC’s decision to test the combination therapy in further studies.

Around 150 patients at 20 locations across China will take part in the EOC study within 24 months.

In a randomized, double-blind study, patients are given paclitaxel together with Efti or a placebo. This means that neither the doctors nor the patients know who received the placebo.

The EOC trial will begin registration early next year and will look at patient progression-free survival, overall survival and overall response rate.

Marc Voigt, CEO of Immutep, hopes that the EOC study will provide similar positive data as the AIPAC study.

« EOC Pharma shares our growing excitement about the potential for combining Efti with paclitaxel chemotherapy for metastatic breast cancer, » said Marc.

« Our ongoing AIPAC study evaluating the same combination already has very encouraging data, including a statistically significant survival benefit of 7. 1 month for patients under 65 years of age and 9. 4 months for patients with low starting monocyte counts, « he continued.

« EOC Pharma’s new study in China brings this innovative new treatment much closer to the metastatic breast cancer patient market, » he added.

Preliminary data from the AIPAC study will be presented today at the San Antonio Breast Cancer Symposium.

EOC is the only Chinese licensee for efti and must contribute to the development of the drug in China.

Immutep is expected to receive key milestone payments from EOC if key development goals are met and will also receive royalties on future sales of the drug in China.

With considerable early promise, it appears in both companies’ best interests to get the drug to market as soon as possible.

Aside from the obvious commercial needs, paclitaxel-efti combination therapy shows the potential to significantly improve clinical outcomes for a cohort of patients at risk.

Xiaoming Zou, CEO of EOC Pharma, says the therapy could help millions of women affected by breast cancer.

« Breast cancer is the most common cancer in Chinese women today, with more than 1. 6 million people are diagnosed and 1. 2 million people die from the disease every year, « Xiaoming said.

« It is very important that we find new ways to improve paclitaxel chemotherapy, which continues to be a standard for the treatment of HER2-negative / HR-positive metastatic breast cancer patients, » he continued.

« Immutep’s recent encouraging AIPAC interim results give us hope that we can improve them. the body’s immune system to give patients better results, « he concluded.

Immutep, ASX, ASX: IMM, Stock, NASDAQ: IMMP, metastatic breast cancer, eftilagimod alpha

World News – CA – Immutep’s breast cancer therapy (ASX: IMM) is for discontinued phase -2 trial in China – The Market Herald
. . Related title :
ASX share of the day: Immutep shares (ASX: IMM) rise 60% in study news
Immutep Updates AIPAC Breast Cancer Study and Announces New Study
Closing Bell: Today &’s largest small cap mover starts at the ASX
Immutep& The Chinese partner starts a clinical phase II study for patients with metastatic breast cancer two studies in China »> Immutep& # 39; s (ASX: IMM) breast cancer therapy for phase two study in China tellt
– IMMP-share: Immunotep-share rises with positive breast cancer data
Immutep shares rise 57% thanks to two big announcements
Immutep 72% after breast cancer study shows promising survival data
Immutep reports statistically significant survival benefit for important patient groups in the ongoing phase IIb AIPAC study . . .
Immutep&’s Chinese partner EOC Pharma starts phase II metastatic breast cancer study


Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: